Frontlight ResearchEarly access
TerminatedEarly phase 1
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
Key facts
- Who runs it
- University of Rochester
- Where
- Rochester, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Early phase 1
- People taking part
- 3 people enrolled
- Started
- 17 May 2022
- Ended
- 9 May 2024
- Type of study
- Interventional
- Treatments tested
- Brivaracetam
- Record updated
- 3 June 2026
- Why it stopped
- lack of enrollment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age ≥ 18 years with pathologic diagnosis of a supratentorial diffuse astrocytic or oligodendroglial tumor
- Patients must be able to provide informed consent
Who cannot take part
- A pre-existing seizure disorder or epilepsy syndrome prior to tumor diagnosis
- Active maintenance therapy with an antiepileptic seizure drug (AED) prior to diagnosis of tumor
- Patients with active suicidal ideation or a history of suicide attempt or other serious psychiatric disorder having required hospitalization within the previous 2 years
- Patients who have experienced an epileptic seizure as the presenting symptom of their brain tumor
- Patients with clinically significant hepatic disease (elevated aminotransferases [bilirubin, alkaline phosphatase] > 3 times upper limit normal)
- Patients with stage 4 or greater renal disease (GFR <30 mL/min/1.73 m2)
- Predicted life expectancy of less than 6 months from the time of screening
- Pregnancy
- Patients who are unable to swallow a tablet
Where in United States
- University of Rochester Medical CenterRochester, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.
The group in the trial
- ExperimentalTreatment being tested
Brivaracetam at a dose of 50 mg twice daily for 6 months
Treatment: Brivaracetam
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 June 2026